Vaccine for glioblastoma after standard treatment
Part of Cancer clinical trials.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with glioblastoma and already completed radiation therapy with temozolomide.
- You must be in fairly good health, able to care for yourself (Karnofsky score of 60% or higher).
- For the first part of the study, your tumor must have a specific marker called HLA-A2 and express a protein called PTPRZ1.
- You must have tumor tissue available for additional testing.
- You must not be taking high doses of steroids (more than 10 mg of prednisone daily).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (UCPVax) with or without pembrolizumab (an immunotherapy) given after standard radiation and chemotherapy for people with a specific type of glioblastoma (MGMT unmethylated). The goal is to see if adding these treatments can help prevent the cancer from coming back.
This trial tests a personalized vaccine (made from your own immune cells and tumor 'neoantigens') combined with the chemotherapy drug temozolomide for people with newly diagnosed glioblastoma. The goal is to see if adding the vaccine helps the immune system better fight the tumor.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to treat glioblastoma that has come back after standard treatment. The vaccine is designed to help your immune system recognize and attack your tumor.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Hear when a new Newly Diagnosed Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.